Managing patients with chronic severe asthma: Rise to the challenge

European Journal of Internal Medicine

Volumn 20, Issue 2, 2009, Pages 114-124

  Polosa, Riccardo ^a   Benfatto, Giuseppe Trifoglio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Biologics; Chronic severe asthma; Differential diagnosis; Immunomodulators; Pharmacotherapy; Steroid refractoriness

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AURANOFIN; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLOSPORIN; GAMMA GLOBIN; GOLD; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; METHOTREXATE;

ABDOMINAL PAIN; ASTHMA; CATARACT; COUGHING; CUSHINGOID SYNDROME; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG FORMULARY; DYSPHAGIA; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART PALPITATION; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; LEUKEMIA; LIVER FUNCTION TEST; MOUTH ULCER; NAUSEA; OSTEOPOROSIS; PARESTHESIA; PATIENT CARE; PRACTICE GUIDELINE; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; STOMATITIS; TACHYCARDIA; THRUSH; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTI-ASTHMATIC AGENTS; ASTHMA; CHRONIC DISEASE; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 62749196135     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.06.010     Document Type: Review

References (102)

1. Masoli M., Fabian D., Holt S., and Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 5 (May 2004) 469-478
2. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 12 (1998) 315-335
3. Braman S.S. Asthma in the elderly. Clin Geriatr Med 19 (2003) 57-75
4. Akinbami L.J., and Schoendorf K.C. Trends in childhood asthma: prevalence, health care utilization, and mortality. Pediatrics 110 (2002) 315-322
5. Barnes P.J., and Woolcock A.J. Difficult asthma. Eur Respir J 12 (1998) 1209-1218
6. Serra-Batlles J., Plaza V., Morejon E., Comella A., and Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 12 (1998) 1322-1326
7. Godard P., Chanez P., Siraudin L., Nicoloyannis N., and Duru G. Costs of asthma are correlated with severity, a 1 year prospective study. Eur Respir J 19 (2002) 61-67
8. Antonicelli L., Bucca C., Neri M., De Benedetto F., Sabbatani P., Bonifazi F., et al. Asthma severity and medical resource utilization. Eur Respir J 23 (2004) 723-729
9. Heaney L.G., and Robinson D.S. Severe asthma treatment: need for characterising patients. Lancet 365 9463 (Mar 12-18 2005) 974-976
10. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 172 2 (Jul 15 2005) 149-160
11. Holgate S.T., and Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 368 (2006) 780-793
12. Moore W.C., and Peters S.P. Severe asthma: an overview. J Allergy Clin Immunol 117 3 (Mar 2006) 487-494
13. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 22 (2003) 470-477
14. Moore W.C., Bleecker E.R., Curran-Everett D., Erzurum S.C., Ameredes B.T., Bacharier L., et al. National Heart, Lung, Blood Institute's Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 119 2 (Feb 2007) 405-413
15. in't Veen J.C., Smits H.H., Hiemstra P.S., Zwinderman A.E., Sterk P.J., and Bel E.H. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med 160 1 (Jul 1999) 93-99
16. in't Veen J.C., Beekman A.J., Bel E.H., and Sterk P.J. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 161 6 (Jun 2000) 1902-1906
17. Booms P., Cheung D., Timmers M.C., Zwinderman A.H., and Sterk P.J. Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma. J Allergy Clin Immunol 99 3 (1997) 330-337
18. Kikuchi Y., Okabe S., Tamura G., Hida W., Homma M., Shirato K., et al. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 330 (1994) 1329-1334
19. Barreiro E., Gea J., Sanjuas C., Marcos R., Broquetas J., and Milic-Emili J. Dyspnoea at rest and at the end of different exercises in patients with near-fatal asthma. Eur Respir J 24 (2004) 219-225
20. de Marco R., Cazzoletti L., Cerveri I., Corsico A., Bugiani M., Accordini S., et al. Are the asthma guideline goals achieved in daily practice? A population-based study on treatment adequacy and the control of asthma. Int Arch Allergy Immunol 138 3 (Nov 2005) 225-234
21. Veen J.C., Smits H.H., Ravensberg A.J., Hiemstra P.S., Sterk P.J., and Bel E.H. Impaired perception of dyspnea in patients with severe asthma. Relation to sputum eosinophils. Am J Respir Crit Care Med 158 4 (1998) 1134-1141
22. Ulrik C.S., and Backer V. Non reversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 14 (1999) 892-896
23. Lange P., Parner J., Vestbo J., Schnohr P., and Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339 (Oct 1998) 1194-1200
24. Hansen E.F., Phanareth K., Laursen L.C., Kok-Jensen A., and Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159 4 Pt 1 (Apr 1999) 1267-1271
25. Lemanske R.F. Is asthma an infectious disease? Thomas A. Neff lecture. Chest 123 3 Suppl. (2003) 385S-390S
26. Bai T.R., Cooper J., Koelmeyer T., Paré P.D., and Weir T.D. The effect of age and duration of disease on airway structure in fatal asthma. Am J Respir Crit Care Med 162 2 Pt 1 (Aug 2000) 663-669
27. Adcock I.M., and Lane S.J. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol 178 (2003) 347-355
28. Rhen T., and Cidlowski J.A. Anti-inflammatory actions of glucocorticoids: new mechanisms for old drugs. N Engl J Med 353 17 (2005) 111-123
29. Weiss S.T., Lake S.L., Silverman E.S., Silverman E.K., Richter B., Drazen J.M., et al. Asthma steroid pharmacogenetics: a study strategy to identify replicated treatment responses. Proc Am Thorac Soc 1 4 (2004) 364-367
30. Gotway M.B., Reddy G.P., Webb W.R., Elicker B.M., and Leung J.W. High-resolution CT of the lung: patterns of disease and differential diagnoses. Radiol Clin North Am 43 3 (2005) 513-542 viii
31. Vignola A.M., Paganin F., Capieu L., Scichilone N., Bellia M., Maakel L., et al. Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 24 6 (Dec 2004) 910-917
32. Bumbacea D., Campbell D., Nguyen L., Carr D., Barnes P.J., Robinson D., and Chung K.F. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 24 1 (Jul 2004) 122-128
33. Gibson P.G., Henry R.L., and Thomas P. Noninvasive assessment of airway inflammation in children: induced sputum, exhaled nitric oxide, and breath condensate. Eur Respir J 16 5 (Nov 2000) 1008-1015
34. Lemiere C., Ernst P., Olivenstein R., Yamauchi Y., Govindaraju K., Ludwig M.S., et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 118 5 (Nov 2006) 1033-1039
35. Bender B.G. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 109 6 Suppl (Jun 2002) S554-559
36. Weinstein A.G. Should patients with persistent severe asthma be monitored for medication adherence. Ann Allergy Asthma Immun 94 2 (Feb 2005) 251-257
37. Cochrane G.M., Horne R., and Chanez P. Compliance in asthma. Respir Med 93 11 (1999) 763-769
38. http://www.motivationalinterviewing.org.
39. D'Souza W.J., Te Karu H., Fox C., Harper M., Gemmell T., Ngatuere M., et al. Long-term reduction in asthma morbidity following an asthma self-management programme. Eur Respir J 11 3 (Mar 1998) 611-616
40. Heaney L.G., Conway E., Kelly C., Johnston B.T., English C., Stevenson M., et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 58 (2003) 561-566
41. Tinkelman D.G., Price D.B., Nordyke R.J., and Halbert R.J. Misdiagnosis of COPD and asthma in primary care patients 40 years and over. J Asthma 43 (2006) 75-80
42. Greenberger P.A. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 110 5 (2002) 685-692
43. Noth I., Strek M.E., and Leff A.R. Churg-Strauss syndrome. Lancet 361 9357 (2003) 587-594
44. ten Brinke A., Sterk P.J., Masclee A.A., Spinhoven P., Schmidt J.T., Zwinderman A.H., et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 26 5 (2005) 812-818
45. Mascia K., Haselkorn T., Deniz Y.M., Miller D.P., Bleecker E.R., Borish L., and TENOR Study Group. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 116 5 (2005) 970-975
46. Bachert C., Patou J., and Van Cauwenberge P. The role of sinus disease in asthma. Curr Opin Allergy Clin Immunol 6 (2006) 29-36
47. Koga T., Oshita Y., Kamimura T., Koga H., and Aizawa H. Characterisation of patients with frequent exacerbation of asthma. Respir Med 100 (2006) 273-278
48. Littner M.R., Leung F.W., Ballard II E.D., Huang B., Samra N.K., and Lansoprazole Asthma Study Group. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest 128 (2005) 1128-1135
49. Kiljander T.O., Harding S.M., Field S.K., Stein M.R., Nelson H.S., Ekelund J., et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 173 10 (May 2006) 1091-1097
50. Gibson P.G., Henry R.L., and Coughlan J.L. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2 (2003) CD001496
51. Weiss S.T., and Shore S. Obesity and asthma: directions for research. Am J Respir Crit Care Med 169 8 (2004) 963-968
52. Le Moual N., Siroux V., Pin I., Kauffman F., and Kennedy S.M. Asthma severity and exposure to occupational asthmogens. Am J Respir Crit Care Med 172 (2005) 440-445
53. Thomson N.C., Chaudhuri R., and Livingston E. Asthma and cigarette smoking. Eur Respir J 24 (2004) 822-833
54. Campbell D.A., Yellowlees P.M., McLennan G., Coates J.R., Frith P.A., Gluyas P.A., et al. Psychiatric and medical features of near fatal asthma. Thorax 50 3 (Mar 1995) 254-259
55. Miles J.F., Garden G.M., Tunnicliffe W.S., Cayton R.M., and Ayres J.G. Psychological morbidity and coping skills in patients with brittle and non-brittle asthma: a case-control study. Clin Exp Allergy 27 10 (Oct 1997) 1151-1159
56. Global Initiative for Asthma. Global strategy for asthma management and prevention. A six part management program. NIH publication number 02-3659 (2006). http://www.ginasthma.org http://www.ginasthma.org (accessed Nov 9, 2006)
57. Gibson P., Powell H., and Ducharme F.J. Long-acting beta2-agonists as an inhaled corticosteroid sparing agent for chronic asthma in adults and children. Cochrane Database Syst Rev 4 (2005) CD005076
58. Tonelli M., Zingoni M., Bacci E., Dente F.L., Di Franco A., Giannini D., et al. Short-term effect of the addition of leukotriene receptor antagonists to the current therapy in severe asthmatics. Pulm Pharmacol Ther 16 4 (2003) 237-240
59. Polosa R. Critical appraisal of antileukotriene use in asthma management. Curr Opin Pulm Med 13 1 (2007) 24-30
60. Rodrigo G.J., and Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe asthma. Chest 123 (2003) 1908-1915
61. Virchow J.C., and Lommatzsch M. Anticholinergic agents in asthma. In: Polosa R., and Holgate S.T. (Eds). Therapeutic Strategies in Asthma: Current Treatments (2007), Clinical Publishing, Oxford 79-90
62. Vatrella A., Ponticiello A., Pelaia G., Parrella R., and Cazzola M. Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma. Pulm Pharmacol Ther 18 2 (2005) 89-92
63. Roberts G., Newsom D., Gomez K., Raffles A., Saglani S., Begent J., et al., North West Thames Asthma Study Group. Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial. Thorax 58 4 (2003) 306-310
64. Beasley R., and Aldington S. Magnesium in the treatment of asthma. Curr Opin Allergy Clin Immunol 7 1 (2007) 107-110
65. Silverman R.A., Osborn H., Runge J., Gallagher E.J., Chiang W., Feldman J., et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest 122 2 (2002) 489-497
66. Jamieson T. Corticosteroids for rheumatic disease. 1. Physiology, pharmacology, and therapeutic strategies. Postgrad Med 79 5 (1986) 239-244
67. Mortimer K.J., and Tattersfield A.E. Benefit versus risk for oral, inhaled and nasal glucocorticosteroids. Immunol Allergy Clin North Am 25 (2005) 523-539
68. Keenan G.F. Management of complications of glucocorticoid therapy. Clin Chest Med 18 (1997) 507-520
69. Tascioglu F., Colak O., Armagan O., Alatas O., and Oner C. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. Rheumatol Int 26 1 (2005) 21-29
70. Lakatos P., Nagy Z., Kiss L., Horvath C., Takacs I., Foldes J., et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 59 Suppl 1 (2000) 48-52
71. Marin M.G. Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Chest 112 (1997) 29-33
72. Aaron S.D., Dales R.E., and Pham B. Management of steroiddependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Respir Med 92 (1998) 1059-1065
73. Davies H., Olson L., and Gibson P. Methotrexate as a steroid-sparing agent for asthma in adults. Cochrane Database Syst Rev 2 (2000) CD000391
74. Mullarkey M.F., Lammert J.K., and Blumenstein B.A. Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med 112 (1990) 577-581
75. Shiner R.J., Katz I., Shulimzon T., Silkoff P., and Benzaray S. Methotrexate in steroid-dependent asthma: long-term results. Allergy 49 7 (Aug 1994) 565-568
76. Comet R., Domingo C., Larrosa M., Moron A., Rue M., Amengual M.J., et al. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study. Respir Med 100 3 (2006) 411-419
77. Muranaka M., Miyamoto T., Shida T., Kabe J., Makino S., Okumura H., et al. Gold salt in the treatment of bronchial asthma: a double-blind study. Ann Allergy 40 2 (Feb 1978) 132-137
78. Nierop G., Gijzel W.P., Bel E.H., Zwinderman A.H., and Dijkman J.H. Auranofin in the treatment of steroid dependent asthma: a double blind study. Thorax 47 5 (May 1992) 349-354
79. Bernstein I.L., Bernstein D.I., Dubb J.W., Faiferman I., and Wallin B. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol 98 2 (Aug 1996) 317-324
80. Alexander A.G., Barnes N.C., and Kay A.B. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339 (1992) 324-328
81. Lock S.H., Kay A.B., and Barnes N.C. Double-blind, placebocontrolled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 153 (1996) 509-514
82. Nizankowska E., Soja J., Pinis G., Bochenek G., Sładek K., Domagała B., et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 8 7 (Jul 1995) 1091-1099
83. Dougados M., Awada H., and Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 47 2 (Feb 1988) 127-133
84. Kornbluth A., Present D.H., Lichtiger S., and Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 92 9 (Sep 1997) 1424-1428
85. Salmun L.M., Barlan I., Wolf H.M., Eibl M., Twarog F.J., Geha R.S., et al. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. J Allergy Clin Immunol 103 5 Pt 1 (1999) 810-815
86. Kishiyama J.L., Valacer D., Cunningham-Rundles C., Sperber K., Richmond G.W., Abramson S., et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol 91 2 (May 1999) 126-133
87. Nelson H.S., Hamilos D.L., Corsello P.R., Levesque N.V., Buchmeier A.D., and Bucher B.L. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 147 2 (Feb 1993) 398-404
88. Garey K.W., Rubinstein I., Gotfried M.H., Khan I.J., Varma S., and Danziger L.H. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 118 6 (Dec 2000) 1826-1827
89. Dean T., Dewey A., Bara A., Lasserson T.J., and Walters E.H. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 1 (2004) CD003270
90. Rosenberg J.L., Wall A.J., Levin B., Binder H.J., and Kirsner J.B. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 69 1 (Jul 1975) 96-99
91. Heurkens A.H., Westedt M.L., and Breedveld F.C. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 151 11 (Nov 1991) 2249-2254
92. Russo C., and Polosa R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond) 109 (2005) 135-142
93. Cazzola M., and Polosa R. Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol 6 (2006) 43-50
94. Howarth P.H., Babu K.S., Arshad H.S., Lau L., Buckley M., McConnell W., et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60 12 (Dec 2005) 1012-1018
95. Berry M.A., Hargadon B., Shelley M., Parker D., Shaw D.E., Green R.H., et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N Engl J Med 354 7 (Feb 2006) 697-708
96. Erin E.M., Leaker B.R., Nicholson G.C., Tan A.J., Green L.M., Neighbour H., et al. The effects of a monoclonal antibody directed against tumour necrosis factor-α (TNF- α) in asthma. Am J Respir Crit Care Med 174 7 (2006) 753-762
97. Edwards C.J., and Polosa R. Study of infliximab treatment in asthma. Am J Respir Crit Care Med 175 2 (2006) 196-197
98. Morjaria J.B., Babu K.S., Holgate S.T., and Polosa R. Tumour necrosis factor-α as a therapeutic target in asthma. Drug Discov Today Ther Strateg 3 3 (2006) 309-316
99. Roberts L., and McColl G.J. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 34 12 (Dec 2004) 687-693
100. Liu A.H. Treatment of asthma with anti-immunoglobulin E monoclonal antibody. Allergy Asthma Proc 27 2 Suppl 1 (Mar-Apr 2006) S24-S28
101. Niebauer K., Dewilde S., Fox-Rushby J., and Revicki D.A. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immun 96 (2006) 316-326
102. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 3 (Mar 2005) 309-316